Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?

ERTÜRK AKSAKAL, Sezin; KORKMAZ, Hilal; Korkmaz, Vakkas

doi:10.5505/aot.2022.50570

Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?

Sezin Ertürk Aksakal, (Department of Gynecology, University of Health Sciences Etlik Zübeyde Hanım Women’s Health Training and Research Hospital, Ankara)

Hilal Korkmaz, (Department of Physiology, Gazi University Faculty of Medicine, Ankara)

Vakkas Korkmaz (Depertment of Gynecologic Oncology, University of Health Sciences Etlik Zübeyde Hanım Women’s Health Training and Research Hospital, Ankara)

ACTA ONCOLOGICA TURCICA

8 0

Yıl: 2022 Cilt: 55 Sayı: 2 Sayfa Aralığı: 85 - 92 Metin Dili: İngilizce DOI: 10.5505/aot.2022.50570 İndeks Tarihi: 21-09-2022

Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?

Öz:

Aim: Uterine sarcomas are one of the aggressive gynecologic malignancies. There is still no optimal test for preoperative diagnosis of uterine sarcomas. The aim of this study was to evaluate the role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and APRI score in predicting preoperative uterine sarcoma. Materials and Methods: Patients operated on between January 2010 and December 2020 histo-pathologically diagnosed as sarcoma were included in the study group. Patients who were histo-pathologically diagnosed with myoma uteri were included as the control group during the same period. Age, BMI (body mass index), gravida, parity, preoperative mean platelet volume (MPV), platelet distribution width (PDW), red cell distribution width (RDW), NLR, PLR and APRI scores were recorded. Results: When comparing patients with fibroids and sarcomas, hemoglobin [12.3 g/dl (6.4-15.4) vs. 11.3 g/dl (6-17), p=0.008, respectively], hematocrit [38.5% (22-48.7) vs. 35.9% (21.4-52.1), p=0.002, respectively] and lymphocyte levels [2.2 103/ L (0.9-13.8) vs. 1.8 103/ L (1-2.6), p=0.001, respectively] were significantly lower and NLR [1.7 (0.2-10.1) vs. 2.3 (1.4-5.9), p=0.001, respectively] and PLR [124 (10.9-352.1) vs. 180.4 (84.9-284.3), p=0.001, respectively] were significantly higher in sarcoma group. The optimal cut-off value for NLR and PLR was calculated to be 2.04 with sensitivity and specificity of 59.4% and 59.5%, respectively, and 150.7 with sensitivity and specificity of 65.6% and 64.7%, respectively. Conclusion: Preoperative NLR and PLR rates can be useful markers for diagnosing uterine sarcoma. Randomized controlled large series studies are necessary to make a definitive statement.

Anahtar Kelime:

Preoperatif Nötrofil Lenfosit Oranı, Platelet Lenfosit Oranı ve APRİ Skoru Uterin Sarkomları Myomlardan Ayırt Edebilir mi?

Öz:

Giriş ve Amaç: Uterin sarkomlar nadir görülen, agresif seyirli jinekolojik kanserlerden biridir. Preoperatif optimal tanı testi hala bulunmamaktadır. Çalışmamızın amacı preoperatif uterin sarkomu öngörmede nötrofil-lenfosit oranı (NLR), platelet-lenfosit oranı (PLR) ve APRİ skoru değerlen-dirmektir. Yöntem ve Gereçler: Ocak 2010 ile Aralık 2020 tarihleri arasında histopatolojik sarkom tanısı alan hastalar çalışmaya dahil edildi. Aynı dönemde histopatolojik myom uteri tanısı alan hastalar kontrol grubu olarak alındı. Yaş, vücut kitle indeksi, gravida, parite, preoperatif ortalama platelet hacmi (MPV), platelet dağılım genişliği (PDW), kırmızı hücre dağılım genişliği (RDW), NLR, PLR and APRİ skoru kaydedildi. Bulgular: Sarkom ve myom tanılı hastalar karşılaştırıldığında, sarkom hastalarında hemoglobin [sırasıyla 12.3 gr/dl (6.4-15.4) ve 11.3 gr/dl (6-17), p=0.008], hematokrit [sırasıyla %38.5 (22-48.7) ve %35.9 (21.4-52.1), p=0.002] ve lenfosit seviyeleri [sırasıyla 2.2 103/ L (0.9-13.8) ve 1.8 103/ L (1-2.6), p=0.001,] anlamlı olarak düşük, NLR [sırasıyla 1.7 (0.2-10.1) ve 2.3 (1.4-5.9), p=0.001] ve PLR [sırasıyla 124 (10.9-352.1) ve 180.4 (84.9-284.3), p=0.001] anlamlı olarak yüksek saptandı. Tartışma ve Sonuç: Preoperatif NLR ve PLR oranları uterin sarkom tanısında kullanılabilecek markırlardır. Bu konuda kesin konuşabilmek adına randomize kontrollü geniş serili çalışmalara ihtiyaç vardır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Harlow BL, Weiss NS, Lofton S. The epidemiology of Sarcomas of the uterus. Journal of National Cancer Institue 1986; 76(3): 399-402.
2. Gezer A, Altınok T, Uludağ S. Endometrial stromal sarcoma: Case report and review of the current literature. Cerrahpaşa Medical Journal 2002; 33(3): 189-92.
3. Otis C, Ocampo A. Protocol for the Examination of Specimens from Patients with Sarcoma of the Uterus, 2013. College of American pathologists, 2013. Available at: http:// www.cap.org/apps/docs/ committees/cancer/cancer_protocols/2013/UterineSarcomaProtocol_3000.pdf (Accessed on April 29, 2014).
4. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. European Journal of Cancer. 1997; 33(6): 907-11.)
5. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstetrics and Gynecology. 1994; 83(3): 414-418.
6. Baird DD, Garrett TA, Laughlin SK, Davis B, Semelka RC, Peddada SD. Short-term change in growth of uterine leiomyoma: tumor growth spurts. Fertility Sterility 2011; 95(1): 242-246.
7. Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premeno-pausal black and white women. Proceedings of the National Academy of Sciences 2008; 105(50) :19887-19892.
8. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncology 2009; (12)10: 1188-11198.
9. Yildirim M, Turkyilmaz E, Avsar AF. Preoperative neutrophil to lymphocyte ratio has a better predictive capacity in diagnosing tubo ovarian abscess. Gynecologic and Obstetric Investigation 2015; 80: 234 239.
10. Torun S, Tunc BD, Suvak B, Yildiz H, Tas A, Sayilir A, et al. Assessment of neutrophil lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity. Clinics and Research in Hepatology and Gastroenterology 2012; 36: 491 497.
11. Caglayan EK, Engin-Ustun Y, Gocmen AY, Sarı N, Seckin L, Kara M, Polat MF. Is there any relationship between serum sirtuin-1 level and neutrophil-lymphocyte ratio in hyperemesis gravidarum? Journal of Perinatal Medicine. 2016; 44(3): 315-320.
12. Dan Nie, Han Gong, Xiguang Mao, Zhengyu Li. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study, Gynecologic Oncology. 2019; (2)152: 259-264.
13. Temur I, Kucukgoz Gulec U, Paydas S, Guzel AB, Sucu M, Vardar MA. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018; 226: 25-29.
14. Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis, Gynecologic Oncology. 2017; 145(6): 584-594.
15. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecologic Oncology. 2010;116(1):131–9.
16. Laparoscopic Power Morcellators. US Food and Drug Administration. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/ucm584463.htm? utm_campaign=12%2F14%2F17%20FDA%20Posts%20New%20Information%20about%20Using%20Laparoscopic%20Power%20Morcellators&utm_medium=email&utm_source=Eloqua (Accessed on December 20, 2017))
17. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. The American Journal of Surgical Pathology. 1994; 18(6): 535-558
18. Valdes-Devesa V, Jimenez MDM, Sanz-Rosa D, Espada Vaquero M, Alvarez Moreno E, Sainz de la Cuesta Abbad R. Preoperative diagnosis of atypical pelvic leiomyoma and sarcoma: the potential role of diffusion-weighted imaging. Journal of Obstetrics and Gynaecolology. 2019; 39(1): 98-104.
19. Tamai K, Koyama T, Saga T, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. European Radiology 2008; 18:723-730.
20. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. International Journal of Gynecological Cancer. 2002; 12(4): 354-361.
21. Rha SE, Byun JY, Jung SE, et al. CT and MRI of uterine sarcomas and their mimickers. American Journal of Roentgenology 2003; 181: 1369-1374.
22. Mao J, Pfeifer S, Zheng XE, Schlegal P, Sedrakyan A. Population- based estimates of the prevalence of uterine sarcoma among patients with leiomyomata undergoing surgical treatment. JAMA Surgery. 2015; 150: 368 –370.
23. Hosh M, Antar S, Nazzal A, et al. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. International Journal of Gynecologic Cancer 2016; 26: 1098-1104.
24. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecologic Oncology 2003; 89 (3):460-469.
25. Chen I, Firth B, Hopkins L, Bougie O, Xie RH, Singh S. Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. JSLS: Journal of the Laparoendoscopic Surgeons 2018; 22(1): e2017.00066.
26. Lindemann K, Vatten L, Ellstrøm-Engh M. The impact of BMI on subgroups of uterine cancer. British Journal of Cancer 2009; 101: 534–536
27. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International Journal of Cancer 2007;120: 378–383.
28. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care.2009; 12(3): 223-226
29. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of Surgical Oncology 2005; 91: 181–184.
30. Selen S, Kilic F, Kimyon Comert G, Unsal M., Kilic C, Karalok A, Turkmen O. and Turan T. Can preoperative inflammatory markers differentiate endometrial cancer from complex atypical hyperplasia/endometrial intraepithelial neoplasia? Journal of Obstetrics and Gynaecology Research. 2020; 46: 1148-1156.
31. Eo WK, Kim KH, Park EJ, et al. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. Journal of Cancer. 2018; 9(7): 1165-1172.
32. Cho HY, Kim K, Kim YB, and No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. Journal of Obstetrics and Gynaecology Research. 2016; 42: 313– 318.
33. Kim HS, Han KH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison, European Journal of Surgical Oncology. 2010: 36 (7); 691-698.
34. Zhang G, Yu X, Zhu L, Fan Q, Lang J. Pre-operative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020; 20(1): 514-521
35. Namkung J, Kim YW, Kim JY et al. Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness. Clinical and Experimental Obstetrics & Gynecology. 2019; 46(6): 953-957.
36. Jeong MJ, Park JH, Hur SY, Kim CJ, Nam HS, Lee YS. Preoperative Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in Uterine Sarcoma. Journal of Clinical Medicine. 2020; 9(9):2898.

APA	ERTÜRK AKSAKAL S, KORKMAZ H, Korkmaz V (2022). Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. , 85 - 92. 10.5505/aot.2022.50570
Chicago	ERTÜRK AKSAKAL Sezin,KORKMAZ Hilal,Korkmaz Vakkas Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. (2022): 85 - 92. 10.5505/aot.2022.50570
MLA	ERTÜRK AKSAKAL Sezin,KORKMAZ Hilal,Korkmaz Vakkas Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. , 2022, ss.85 - 92. 10.5505/aot.2022.50570
AMA	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. . 2022; 85 - 92. 10.5505/aot.2022.50570
Vancouver	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. . 2022; 85 - 92. 10.5505/aot.2022.50570
IEEE	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V "Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?." , ss.85 - 92, 2022. 10.5505/aot.2022.50570
ISNAD	ERTÜRK AKSAKAL, Sezin vd. "Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?". (2022), 85-92. https://doi.org/10.5505/aot.2022.50570

APA	ERTÜRK AKSAKAL S, KORKMAZ H, Korkmaz V (2022). Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. ACTA ONCOLOGICA TURCICA, 55(2), 85 - 92. 10.5505/aot.2022.50570
Chicago	ERTÜRK AKSAKAL Sezin,KORKMAZ Hilal,Korkmaz Vakkas Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. ACTA ONCOLOGICA TURCICA 55, no.2 (2022): 85 - 92. 10.5505/aot.2022.50570
MLA	ERTÜRK AKSAKAL Sezin,KORKMAZ Hilal,Korkmaz Vakkas Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. ACTA ONCOLOGICA TURCICA, vol.55, no.2, 2022, ss.85 - 92. 10.5505/aot.2022.50570
AMA	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. ACTA ONCOLOGICA TURCICA. 2022; 55(2): 85 - 92. 10.5505/aot.2022.50570
Vancouver	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?. ACTA ONCOLOGICA TURCICA. 2022; 55(2): 85 - 92. 10.5505/aot.2022.50570
IEEE	ERTÜRK AKSAKAL S,KORKMAZ H,Korkmaz V "Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?." ACTA ONCOLOGICA TURCICA, 55, ss.85 - 92, 2022. 10.5505/aot.2022.50570
ISNAD	ERTÜRK AKSAKAL, Sezin vd. "Can Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and APRI Score Reliably Differentiate Uterine Sarcomas from Leiomyomas?". ACTA ONCOLOGICA TURCICA 55/2 (2022), 85-92. https://doi.org/10.5505/aot.2022.50570